virginiamycin S1   Click here for help

GtoPdb Ligand ID: 13755

Synonyms: staphylomycin S | virgimycin
Compound class: Natural product
Comment: Virginiamycin S1 is a streptogramin antibacterial produced by a Streptomyces sp. related to S. virginiae [5]. It is isolated as part of a virginiamycin complex containing M components (M1 and M2) and S components (S1-S4)(reviewed in [1]). Virginiamycin S1 and pristinamycin IIA (virginiamycin M1) are the major components of virginiamycin [2], an antibacterial used in veterinary medicine and also in animal husbandry as a growth promoter.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 17
Hydrogen bond donors 4
Rotatable bonds 7
Topological polar surface area 224.19
Molecular weight 823.89
XLogP 1.42
No. Lipinski's rules broken 2

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC[C@@H]1C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC3=CC=CC=C3)C(=O)N4CCC(=O)C[C@H]4C(=O)N[C@@H](C5=CC=CC=C5)C(=O)O[C@H](C)[C@@H](C(=O)N1)NC(=O)C6=NC=CC=C6O
Isomeric SMILES CC[C@@H]1C(=O)N2CCC[C@H]2C(=O)N([C@H](C(=O)N3CCC(=O)C[C@H]3C(=O)N[C@H](C(=O)O[C@@H]([C@@H](C(=O)N1)NC(=O)C4=C(C=CC=N4)O)C)C5=CC=CC=C5)CC6=CC=CC=C6)C
InChI InChI=1S/C43H49N7O10/c1-4-29-40(56)49-21-12-17-30(49)41(57)48(3)32(23-26-13-7-5-8-14-26)42(58)50-22-19-28(51)24-31(50)37(53)47-35(27-15-9-6-10-16-27)43(59)60-25(2)34(38(54)45-29)46-39(55)36-33(52)18-11-20-44-36/h5-11,13-16,18,20,25,29-32,34-35,52H,4,12,17,19,21-24H2,1-3H3,(H,45,54)(H,46,55)(H,47,53)/t25-,29-,30+,31+,32+,34+,35+/m1/s1
InChI Key FEPMHVLSLDOMQC-IYPFLVAKSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
Virginiamycin is approved by the US FDA for use in animal production as a growth promoter and in veterinary medicine. It is administered as a medicated feed and indicated for the control and treatment of swine dysentery and for the prevention of necrotic enteritis caused by Clostridium perfringens in poultry. Virginiamycin was used as a growth promoter in the European Union, but authorisation was withdrawn in 1998.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Both components of virginiamycin bind to the 50S subunit of the bacterial ribosome, acting synergistically to inhibit protein synthesis [3].